Skip to content

Common and Specific Information From Neuroimaging and Smartphone

Individual Gait Pattern and MRI Lesion Load to Quantify Gait Impairment in MS: A Cross Sectional Study.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05482906
Acronym
MS-CSI
Enrollment
100
Registered
2022-08-01
Start date
2023-04-03
Completion date
2026-06-30
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Wearable sensor, Gait, MRI

Brief summary

Gait alteration is frequent in MS and limitation in walking ability is a major concern in MS patients. Umanit and LMJL (Nantes university) has developed a device call egait to assess walking ability in individuals (eg MS patients).

Detailed description

This device consists in a commercialized IMU sensor (MetaMotionR Sensor, Mbientilab) worn at the right hip, a smartphone app and dedicated algorithm/mathematical model to extract raw sensor data and calculate individual gait pattern (IGP). This IGP consists of a curve, based on quaternion and representing the rotation recorded by the IMU during an average gait cycle. Pursue previous works conducted on (IGP to assess) gait alteration in MS by adding (to IGP) new information from MRI.

Interventions

OTHEReGait

IMU sensor (as part of eGait device) worn at the hip during T25FW

Sponsors

Nantes University Hospital
Lead SponsorOTHER
Rennes University Hospital
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

: * Diagnosis of MS based on McDonald criteria (including Relapsing-remitting and progressive MS) * Over 18 years old /age greater than 18 years * Patients followed at Nantes university hospital or Rennes university hospital * Last known EDSS before inclusion ranging from 0 to 6 inclusive/EDSS of 0 to 6 inclusive, prior inclusion * No relapse within 3 months * With a Medullar MRI planed as part as usual care * MRI scan can be performed within a maximum of 4 months after or before the walking test. * Affiliated person or beneficiary of a social security scheme

Exclusion criteria

: * Bilateral aid needed to walk * Women who are pregnant * Patient having expressed their opposition * Patient under guardianship or security measure

Design outcomes

Primary

MeasureTime frameDescription
Clustering analyze based on IGPAt the inclusionIGP consists of a curve, based on quaternion and representing the rotation recorded by the IMU during an average gait cycle (0-1).
Clustering analyze based on EDSS scoreAt the inclusionEDSS is an ordinal scale measuring disability and ranging from 0 (normal examination) to 10 (death due to MS) in a 0,5-point increments from score 1.
Clustering analyze based on MRI lesion loadAt the inclusionMRI characteristics are spinal and extraspinal lesion volumes.

Secondary

MeasureTime frameDescription
Correlation with disabilityAt the inclusionCorrelation of IGP obtained during a walk of 25 feet with Expanded Disability Status Scale (EDSS). EDSS is an ordinal scale measuring disability and ranging from 0 (normal examination) to 10 (death due to MS) in a 0,5-point increments from score 1. Here EDSS of 0 to 2 inclusive defined as mild, 2,5 to 4 inclusive as moderate and EFDSS of 4,5 to 6 inclusive defined as severe
Correlation with MRI lesion loadAt the inclusionAdd lesion load (Spinal and extraspinal lesion volume) from MRI to previous correlation.
Building a predictive model for lesion load involving in walk ability from IGPAt the inclusionRoot mean square error between observed and lesion load predicted by the model, calculated by cross-validation.
Building a predictive model for group belonging from group established in main outcome based on IGPAt the inclusionMulticlass accuracy between real and predict group, calculated by cross-validation

Countries

France

Contacts

CONTACTDavid LAPLAUD, PHD
david.laplaud@chu-nantes.fr33 2 40 16 52 00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026